Issue 3 — April 29, 2026

THIS WEEK

The most anticipated metabolic liver disease trial of 2026 is approaching its readout window, and most people covering the GLP-1 space have not explained why survodutide is a different compound from tirzepatide in the ways that actually matter. We break down the Phase 2 MASH data, the mechanism behind the glucagon receptor advantage for liver disease, and why the second receptor choice in a dual agonist changes the entire clinical profile. On the regulatory front, Issue 2 covered seven peptides moving toward FDA advisory panel review in July. The April 15 announcement actually covered twelve. We cover the five that were missed and update the complete picture.

Study of the Week

The GLP-1/Glucagon Dual Agonist Built Specifically for Fatty Liver Disease

Survodutide — Boehringer Ingelheim and Zealand Pharma — Phase 3 SYNCHRONIZE and LIVERAGE Programs

Survodutide is a once-weekly subcutaneous dual agonist that activates the GLP-1 receptor and the glucagon receptor. That second receptor is not GIP, which is what tirzepatide uses. The distinction sounds technical but it has real clinical consequences, particularly for patients with fatty liver disease, and it is the reason survodutide has a development story that is genuinely differentiated from every other compound in the metabolic space right now.

The Phase 2 obesity data is strong. In the primary obesity trial, survodutide produced 18.7% weight loss at 46 weeks in completers, with 40% of participants achieving 20% or greater weight loss. The weight loss curve had not plateaued at trial end, suggesting the full efficacy potential had not been reached at 46 weeks. That is a meaningful signal in a class where plateau effects tend to appear clearly within the trial window.

The more distinctive data is in MASH. Metabolic dysfunction-associated steatohepatitis is a progressive liver disease caused by fat accumulation and inflammatory damage to hepatocytes. It affects an estimated 6 to 8% of the global adult population and has no approved pharmacotherapy beyond the recently approved resmetirom. In survodutide's Phase 2 MASH trial, 83% of participants achieved histological liver improvement at 48 weeks, with 62% achieving MASH resolution. These are large effect sizes for a disease that is notoriously difficult to treat and where histological endpoints require liver biopsy to confirm.

The glucagon receptor component is the mechanistic reason for this liver-specific profile. Glucagon receptor activation directly stimulates hepatic fatty acid oxidation and reduces liver fat accumulation through pathways that GLP-1 and GIP receptor agonism do not reach with the same potency. The liver is the primary site of glucagon receptor expression. When you activate GLP-1 and glucagon together, you get appetite suppression and reduced caloric intake via GLP-1, plus direct hepatic fat oxidation via glucagon. Tirzepatide's GIP component drives its own advantages, particularly in insulin sensitization, but the hepatic fat oxidation mechanism is not its primary strength.

The Phase 3 program is the SYNCHRONIZE program for obesity (SYNCHRONIZE-1 and SYNCHRONIZE-2, which enrolled 1,481 total participants) and the LIVERAGE program for MASH. Last participant visits for SYNCHRONIZE-1 and SYNCHRONIZE-2 are expected in the first half of 2026, with analyzed results anticipated later in 2026. The FDA has granted survodutide Breakthrough Therapy designation for MASH and Fast Track designation for NASH, along with EMA PRIME scheme acceptance.

The bottom line: survodutide is not another tirzepatide competitor in a crowded field. It is the compound most likely to establish a standard of care in MASH, which currently has almost none. The obesity data is strong enough to be competitive but the liver data is where the real differentiation lives.

Full premium section continues with a detailed comparison of survodutide vs tirzepatide efficacy data, the SYNCHRONIZE-2 baseline characteristics published in Diabetes, Obesity and Metabolism in February 2026, and the LIVERAGE MASH program timeline.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use